Employing in vitro assays, we examined the possibility that immunodepletion of Dkk-1 or administration of GSK3β inhibitors could represent an adjunct therapy for this disease by improving osteogenic tissue repair adjacent to the tumour. The gene discussed is DKK1; the disease is neoplasm.